A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis

Multiple Sclerosis

Volumn 1, Issue 6, 1996, Pages 339-342

  Van Oosten, B W ^a   Lai, M ^b   Barkhof, F ^a   Miller, D H ^b   Moseley, I F ^d   Thompson, A J ^b   Hodgkinson, S ^c   Polman, C H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d NONE

Author keywords

Anti CD4 antibodies; Magnetic resonance imaging; Multiple sclerosis; Treatment; Trial design

Indexed keywords

CD4 ANTIGEN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0030178003     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600100611     Document Type: Article

References (24)

1. ffrench-Constant C. (1994) Pathogenesis of multiple sclerosis. Lancet 343: 271-275.
2. Traugott U, Reinherz EL, Raine CS. (1982) Multiple sclerosis: distribution of T-cell subsets within active chronic lesions. Science 219: 308-310.
3. Traugott U. (1987) Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. J Neuroimmunol 16: 283-302.
4. Hayashi T et al. (1988) Dual label immunocytochemistry of the active multiple sclerosis lesion: major histocompatibility complex and activation antigens. Ann Neurol 24: 523-531.
5. Pettinelli CD, McFarlin DE. (1981) Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+2-lymphocytes. J Immunol 127: 1420-1423.
6. Holda JH, Swanborg RH. (1982) Autoimmune effector cells II. Transfer of experimental allergic encephalomyelitis with a subset of T lymphocytes. Eur J Immunol 12: 453-455.
7. Mokhtarian F, McFarlin DE, Raine CS. (1984) Adoptive transfer of myelin basic protein sensitised T cells produces chronic relapsing demyelinating disease in mice. Nature 309: 356-358.
8. Brostoff SW, Mason DW. (1984) Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognized T helper cells. J Immunol 133: 1938-1942.
9. Waldor MK et al. (1985) Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T cell subset marker. Science 227: 415-417.
10. O'Neill JK et al. (1993) Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J Neuroimmunol 45: 1-14.
11. Hodgkinson S et al. (1992) Phase I study of chimeric anti-CD4 monoclonal antibody in multiple sclerosis. Neurology 42 (Suppl 3): 209.
12. Lindsey JW et al. (1994) Phase clinical study of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 44: 413-419.
13. Lindsey JW et al. (1994) Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 36: 183-189.
14. Harris JO et al. (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29: 548-555.
15. Thompson AJ et al. (1992) Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 42: 60-63.
16. Thompson AJ et al. (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29: 53-62.
17. Miller DH, Barkhof F, Nauta JJP. (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116: 1077-1094.
18. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 122: 6-14.
19. McFarland HF et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758-766.
20. Whitaker JN, McFarland HF, Rudge P, Reingold SC. (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1: 37-47.
21. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for reasearch protocols. Ann Neurol 13: 227-231.
22. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
23. Dalesandro MR et al. (1993) Effects of isotype and Fc region on in vitro function of a mouse/human chimeric CD4 antibody. Int Immunol 5: 283-291.
24. Miller DH et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry 54: 683-688.